Drugs / SCG142
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06544720 | Aug 2023 → Dec 2025 overdue | anal carcinoma, cervical cancer, head and neck cancer, penile cancer +3 | The Affiliated Hospital of Qingdao University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06505551 | Oct 2024 → Dec 2026 expected | anal squamous cell carcinoma, cervical squamous cell carcinoma, head and neck cancer, human papillomavirus-related penile squamous cell carcinoma +2 | SCG Cell Therapy Pte. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCG142 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06544720 ↗ |
| Modality | Cell therapy | “Autologous SCG142 TCR T Cells” NCT06505551 ↗ |